Epithalon
Longevity and telomere peptide
Also known as Epitalon, AEDG, Epithalamin
- Evidence grade
- CSmall or early human studies onlyScale
- Half-life
- Not well characterized in humans
- Schedule
- Daily during short cycles, subcutaneous
- Maintenance amount
- 10.00 mg
- Vial sizes sold
- 10 mg, 50 mg
Where a value is not established in people, this table says so rather than filling the box.
Epithalon is a synthetic tetrapeptide modeled on epithalamin, an extract of the pineal gland. It was developed in Russia and studied for its effects on aging markers, sleep-wake rhythm and telomere biology.
Epithalon is reported to activate telomerase, the enzyme that maintains protective telomere caps on chromosomes, which may slow certain aging markers. It is also linked to a normalized melatonin rhythm and regulation of gene expression tied to the pineal axis. Some long-running cohort work from its developers suggests effects on age-related markers. Independent replication outside the original research groups is limited.
Human evidence comes mostly from older trials by the developers with little independent replication.
- Studied for supporting telomerase activity linked to cellular aging
- Reported to help normalize melatonin and sleep-wake rhythm
- Explored for general healthy-aging and antioxidant markers
- Short cycled protocols keep exposure low
- Injection-site redness or irritation
- Drowsiness in some users
- Theoretical concern that telomerase activation could influence cell growth
- Long-term independent safety data is lacking
A summary of the research, not medical advice. Individual benefits and risks vary, and for some of these compounds the human evidence is still early.
Epithalon is typically studied and used in short courses rather than continuously. Reports describe sleep and circadian changes within the first one to two weeks of a course, with courses generally running 10 to 20 days.
Read the full timeline →Drawn from published trial data and how the research community commonly describes this stretch. Not a fixed schedule and not medical advice.
Daily during short cycles, subcutaneous. For research reference only, not medical advice.
| Phase | Amount |
|---|---|
| Cycle (10–20 days) | 5–10 mg daily |
| Off cycle | none, repeat a few times a year |
Used in short cycles rather than continuously.
A rough shopping estimate at the maintenance amount. Your real needs shift with your dose and titration.
| Item | 8-week plan | 12-week plan | 16-week plan |
|---|---|---|---|
| Peptide vials (10 mg) | 56 | 84 | 112 |
| Insulin syringes (U-100) | 56 | 84 | 112 |
| Bacteriostatic water (10 mL) | 12 | 17 | 23 |
| Alcohol swabs (100-count box) | 2 | 2 | 3 |
Lyophilized: Keep the sealed powder cold and dark, near -20 °C, dry and out of light.
Reconstituted: Refrigerate the mixed vial at 2 to 8 °C and use within about 2 to 3 weeks.
Let a cold vial reach room temperature before you open it, so it takes on less condensation.
How strong is the evidence for Epithalon?
We grade it C on a four-point scale. Mostly older trials run by the developers, with little independent replication.
What is the half-life of Epithalon?
It is not well characterized in humans. Published pharmacokinetic data for Epithalon is thin, so any specific figure you see quoted should be treated with caution.
What amount of Epithalon is used in the research?
Cycle (10–20 days): 5–10 mg daily. Off cycle: none, repeat a few times a year. Used in short cycles rather than continuously.
How is Epithalon stored once reconstituted?
Refrigerate the mixed vial at 2 to 8 °C and use within about 2 to 3 weeks.
